Ordering of the N‑Terminus of Human MDM2 by Small Molecule Inhibitors

Restoration of p53 function through the disruption of the MDM2-p53 protein complex is a promising strategy for the treatment of various types of cancer. Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new class of MDM2 inhibitors, the piperidinones....

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Chemical Society Vol. 134; no. 41; pp. 17059 - 17067
Main Authors Michelsen, Klaus, Jordan, John B, Lewis, Jeffrey, Long, Alexander M, Yang, Evelyn, Rew, Yosup, Zhou, Jing, Yakowec, Peter, Schnier, Paul D, Huang, Xin, Poppe, Leszek
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 17.10.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Restoration of p53 function through the disruption of the MDM2-p53 protein complex is a promising strategy for the treatment of various types of cancer. Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new class of MDM2 inhibitors, the piperidinones. While these compounds bind to the same site as previously reported for small molecule inhibitors, such as the Nutlins, data presented here demonstrate that the piperidinones also engage the N-terminal region (residues 10–16) of human MDM2, in particular, Val14 and Thr16. This portion of MDM2 is unstructured in both the apo form of the protein and in MDM2 complexes with p53 or Nutlin, but adopts a novel β-strand structure when complexed with the piperidinones. The ordering of the N-terminus upon binding of the piperidinones extends the current model of MDM2-p53 interaction and provides a new route to rational design of superior inhibitors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-7863
1520-5126
DOI:10.1021/ja305839b